SynthesisPediatric research2026
Neonatal Encephalopathy biomarkers: outcome prediction from blood samples: systematic review and meta-analysis.
Synthesis in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal profile of serum orexin-A in neonatal hypoxic-ischemic encephalopathy: a prospective longitudinal study.BMC pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomarkers are important for early diagnosis, guiding prognosis, and identifying potential therapeutic agents. Many biomarkers have been investigated as potential prognostic markers in Neonatal Encephalopathy (NE), none are measured routinely. We examined current evidence of serum biomarkers to predict outcome.
methodsWe prospectively registered with PROSPERO. We searched EMBASE, PubMed, World of Science, and the Cochrane Library databases for studies of biomarkers in NE. We dichotomised participants by normal or adverse outcome and calculated the mean difference (MD) in biomarkers between groups.
resultsLiterature search provided 3046 results. 98 studies of >20 different biomarkers were eligible. We completed meta-analyses, including 47 studies, for serum interleukin (IL)-1β, IL-6, IL-8, IL-10, Neuron Specific Enolase (NSE), S100, and Tumour Necrosis Factor (TNF)-α. Higher IL-6 70.22 pg/ml (95% confidence interval (CI) 0.55, 139.89), IL-8 15.72 pg/ml (95% CI 3.59, 27.85), NSE 38.95 pg/ml (95% CI 18.33, 59.57), and TNF-α 20.84 pg/ml (95% CI 6.24, 35.45) were associated with adverse long-term outcome. Higher IL-6 22.57 pg/ml (95% CI 0.66, 44.49) and lactate 4.5 mg/dL (95% CI 0.66, 44.49) were associated with adverse short-term outcomes.
conclusionSeveral biomarkers especially provide promising prognostic value in NE. Greater uniformity in biomarker outcome reporting would allow improved evidence synthesis. IMPACT STATEMENT: Elevated biomarkers such as Serum IL-6, IL-8, NSE, and TNF-α were associated with adverse long-term outcomes in NE and are promising as surrogate biomarkers of early outcomes Small sample size, lack of uniformity of timing and sampling, as well as analysis, make definitive conclusions challenging. Future collaboration to standardise timing and analysis of biomarkers in larger international cohorts would facilitate translation to the bedside.
Identifiers
42209719What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.